MediWound to Report Second Quarter 2026 Financial Results

Rhea-AI Summary

MediWound (Nasdaq: MDWD) will release its second quarter 2026 financial results for the period ended June 30, 2026 on Thursday, August 13, 2026, followed by a management-hosted conference call and live webcast at 8:30 a.m. Eastern Time to discuss results and provide a corporate update.

Argus Jul 29 session

-1.85% close to close Open Argus

Details

News Market Reaction – MDWD

On Jul 29, the day this news came out, MDWD closed 1.85% below the previous close.

Data tracked by StockTitan Argus for the Jul 29 session.

Key Figures

Reporting period: Second quarter 2026 Quarter-end date: June 30, 2026 Results release date: August 13, 2026 +1 more

Reporting period

Second quarter 2026

Financial results announcement

Quarter-end date

June 30, 2026

Second-quarter reporting period

Results release date

August 13, 2026

Scheduled financial results release

Conference call time

8:30 a.m. Eastern Time

August 13, 2026 webcast and conference call

Previous Earnings date Reports

2 past events · Latest: May 07

Same Type 2 events

1. May 07

   earnings date

   24h Move

   -0.6%

   Scheduled Q1 2026 results release followed by management webcast and corporate update.

2. Feb 19

   earnings date

   24h Move

   +0.9%

   Scheduled Q4 and full-year 2025 results release with management conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

biologic, eschar, debridement, fda-approved

4 terms

biologic medical

"The company’s FDA-approved biologic, NexoBrid®, is indicated"

A biologic is a medicine made from living cells or organisms—such as proteins, antibodies or vaccines—rather than being chemically synthesized. Investors watch biologics closely because they are expensive and complex to develop and manufacture, often enjoy strong market pricing and protections, and face unique regulatory and supply risks; think of them like handcrafted specialty goods versus mass-produced items with higher potential reward and higher production risk.

eschar medical

"for the enzymatic removal of eschar in thermal burns"

A dry, dark scab of dead tissue that forms over a wound or ulcer when skin cells and blood supply have been damaged; it’s the crusty layer doctors inspect to judge healing or infection. For investors, eschar matters in healthcare contexts because its presence, size, or changes can signal how well a treatment, device or wound-care product is working, or indicate complications that may affect clinical outcomes and regulatory reviews.

debridement medical

"investigational therapy for the debridement of chronic wounds"

Debridement is the medical removal of dead, infected, or damaged tissue and foreign material from a wound to promote healing, similar to pruning dead branches so new growth can flourish. For investors, it matters because how debridement is performed — by drugs, devices, dressings, or procedures — affects clinical outcomes, product demand, reimbursement decisions, regulatory approval pathways, and the financial prospects of companies offering those solutions.

fda-approved regulatory

"The company’s FDA-approved biologic, NexoBrid®"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MediWound to Report Second Quarter 2026 Financial Results

Conference Call and Webcast Scheduled for Thursday, August 13 at 8:30 a.m. Eastern Time

YAVNE, Israel, July 29, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2026, on Thursday, August 13, 2026.

On the same day, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Conference Call & Webcast Details
Toll-Free:                1-844-676-8833
Israel:                     1-80-921-2373
International:          1-412-634-6869
Webcast:                Click HERE

To access the call, participants should dial the applicable telephone number above at least five minutes prior to the start of the call.  A webcast replay will be available in the Investor Relations section of the MediWound website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid^®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, the European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx^®, is an investigational therapy for the debridement of chronic wounds, with the potential to become a new standard of care in wound management. 

For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).

MediWound Contacts:                                                        

Hani Luxenburg                                                Daniel Ferry
Chief Financial Officer                                      Managing Director
MediWound Ltd.                                                LifeSci Advisors, LLC
ir@mediwound.com                                          daniel@lifesciadvisors.com        

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will MediWound (MDWD) report its Q2 2026 financial results?

MediWound will report its Q2 2026 financial results on Thursday, August 13, 2026. According to MediWound, the release covers the quarter ended June 30, 2026 and will be followed by a conference call and live webcast the same morning.

What time is MediWound's Q2 2026 earnings conference call on August 13, 2026?

MediWound’s Q2 2026 earnings conference call starts at 8:30 a.m. Eastern Time on August 13, 2026. According to MediWound, management will discuss financial results and provide a corporate update during the call and simultaneous live webcast.

How can investors join the MediWound (MDWD) Q2 2026 earnings call by phone?

Investors can join by dialing 1-844-676-8833 toll-free in the U.S., 1-80-921-2373 in Israel, or 1-412-634-6869 internationally. According to MediWound, participants should call at least five minutes before the 8:30 a.m. Eastern Time start.

Will a replay of MediWound's Q2 2026 earnings webcast be available for MDWD shareholders?

Yes, a replay of the Q2 2026 webcast will be available after the event. According to MediWound, investors can access the replay through the Investor Relations section of the company’s website following the August 13, 2026 conference call and webcast.

What products and pipeline does MediWound (MDWD) highlight in its July 29, 2026 update?

MediWound highlights NexoBrid, an FDA-approved biologic for enzymatic removal of eschar in thermal burns, and EscharEx, an investigational debridement therapy for chronic wounds. According to MediWound, NexoBrid is marketed in the U.S., EU, Japan, and additional markets.